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ORIGINAL RESEARCH
Predictive Value of Midtrimester
Universal Cervical Length Screening
Based on Parity
Joshua I. Rosenbloom, MD, MPH , Nandini Raghuraman, MD, MS, Lorene A. Temming, MD, MSCI,
Molly J. Stout, MD, MSCI, Methodius G. Tuuli, MD, MPH, Jeffery M. Dicke, MD,
George A. Macones, MD, MSCE, Alison G. Cahill, MD, MSCI
Objectives—To evaluate the effect of parity on performance characteristics of
midtrimester cervical length (CL) in predicting spontaneous preterm birth (sPTB)
before 37 weeks.
Methods—This was a retrospective cohort study of 13,508 women with no his-
tory of sPTB undergoing universal transvaginal CL screening at 17 to 23 weeks’
gestation from 2011 to 2016. Patients who declined screening or with unknown
delivery outcomes were excluded. Areas under the receiver operator characteris-
tic curves were used to assess and compare the predictive ability of CL screening
for sPTB. The sensitivity, specificity, and positive and negative predictive values
were estimated for specific CL cutoffs for prediction of sPTB.
Results—There were 20,100 patients, of whom 2087 (10%) declined screening and
4505 (22%) did not meet inclusion criteria. Of the remaining 13,508 patients, 43%
were nulliparous. The incidence rates of sPTB were 6.5% in nulliparas and 4.9% in
multiparas (P < .001). The mean CLs were 39.9 mm in nulliparas and 41.8 mm in
multiparas (P < .001), and those of the first percentiles were 19.0 mm in nulliparas
and 24.0 mm in multiparas. Cervical length was significantly more predictive of sPTB
in nulliparas (area under the curve, 0.67; 95% confidence interval, 0.63–0.70; versus
0.61, 95% confidence interval, 0.57–0.63; P = .008). At CL cutoffs of 10, 15, 20, and
25 mm or less, the sensitivity was lower in multiparas, and the specificity was compara-
ble between the groups.
Conclusions—Midtrimester CL is less predictive of sPTB in multiparas com-
pared to nulliparas. The poor predictive ability, especially in multiparas, calls into
question the value of universal CL screening in this population.
Key Words—cervical length; obstetrics; parity; preterm birth
Spontaneous preterm birth (sPTB) remains a major public healthproblem, and identification of ways to reduce the rate of sPTB is apriority in obstetric research.1 Midtrimester universal transvaginal
cervical length (TVCL) screening has been proposed as an effective
screening tool for preterm birth (PTB), although controversy
remains.2–8 Indeed routine cervical length (CL) ultrasound (US) is
not currently recommended by the International Society of Ultrasound
inObstetrics andGynecology or the AmericanCollege of Obstetricians
and Gynecologists.1,9 Part of the reason for this controversy is that in
women with singleton gestations, the sensitivity of a short cervix for
PTB is poor, ranging from16% to45%with a positive predictive valueof
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6% to 30%depending on the underlying incidence of PTB
and the exact end point studied.5,10–12
Given the limited test characteristics of TVCL
screening in the general obstetric population, it would be
beneficial to clarify whether the test performs better in a
certain subpopulation. In particular, since a history of
full-term birth is protective against future PTB, it is
unclear how well CL screening performs in multiparous
patients with no history of sPTB compared to nul-
liparous patients.13–16 However, current guidelines for
midtrimester CL screening do not differentiate between
nulliparous and multiparous patients. Therefore, our
objective was to evaluate the effect of parity on perfor-
mance characteristics of midtrimester CL in predicting
sPTB before 37 weeks. We hypothesized that single
midtrimester TVCL screening would have less predictive
utility in multiparous patients with no history of sPTB
compared to nulliparous patients.
Materials and Methods
This was a secondary analysis of a retrospective cohort
study of all patients undergoing midtrimester TVCL
screening from 2011 to 2016 under a universal CL
screening program at Washington University School of
Medicine in St Louis.17 Starting in July 2011, our institu-
tion initiated universal TVCL screening in women with
viable singleton pregnancies without current or planned
cerclage, between gestational ages of 17 weeks and
23 weeks 6 days, in an opt-out fashion. Transvaginal CL
measurements were obtained by trained sonographers
using a standard technique in accordance with the Cervi-
cal Length Education and Review Program guidelines
(however, the sonographers in our institution are not
formally certified by this program).17–19 The original
study was through 2014, and this study included patients
through 2016. The details of the original study have been
published previously.17 The study was conducted after
approval from the Washington University School of
Medicine in St Louis Human Research Protection
Office. A waiver of consent was obtained, and informed
consent was not required because of the retrospective
nature of the study.
Patients were included in the study if they were car-
rying a viable singleton gestation and were either nullipa-
rous or had a history of at least 1 prior full-term
(≥37 weeks) birth and no history of sPTB (defined as
birth from 20 weeks 0 days through 36 weeks and
6 days). Patients with a history of sPTB were excluded,
as they are not the intended target of “universal” CL
screening but instead undergo alternative prophylactic
strategies (eg, 17-hydroxyprogesterone and serial CL
measurements with consideration of cerclage).14 Patients
were also excluded if they declined CL measurement
(although their baseline characteristics were compared
to those of patients who accepted screening) or if their
delivery outcome was unknown. Patients with a history
of iatrogenic PTB (that is, any PTB unrelated to sponta-
neous preterm labor or spontaneous preterm premature
rupture of membranes) and who had no history of a dif-
ferent pregnancy with a full-term birth were excluded.
For patients with more than 1 pregnancy during the
study period, only the first pregnancy was included.
Patients with a CL of 20mmor less were considered
to have a short cervix and were offered treatment
according to our institutional protocol and national
guidelines.1 Patients with CL of greater than 20 mm but
less than 25 mm were considered to have a borderline
short cervix and were strongly recommended to return
for additional measurement before 24 weeks. If patients
had additional CLmeasurements before 23 weeks 6 days,
the shortest one was used for analysis in this study.17
Clinical and demographic data in our US data-
base includes details regarding medical and obstetric
histories, pregnancy complications, and delivery and
neonatal outcomes for all women undergoing prena-
tal US examinations at our institution. Demographic
and medical information, including age, race/ethnicity
(obtained by self-report), tobacco use, body mass
index (BMI), and gestational age, is entered prospec-
tively at the time of the US examination, and neonatal
and pregnancy outcomes are obtained after delivery
through medical record review or by telephone con-
tact with the patient, provider, or both. We catego-
rized race/ethnicity as African American, white, or
other. Gestational age was based on the last menstrual
period if in agreement with first-trimester US within
7 days or with a second-trimester scan within 14 days.
Otherwise, the estimated due date and gestational age
were determined on the basis of the earliest US.
Baseline demographic characteristics were com-
pared between multiparous and nulliparous patients
by routine summary measures. We compared CL
measurements between nulliparous and multiparous
patients, including the mean, standard deviation, and
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1st, 5th, and 10th percentiles. We then created receiver
operating characteristic (ROC) curves for the relation-
ship between CL and sPTB before 37 weeks 34 weeks
and calculated the area under the curve (AUC) and
95% confidence interval (CI). For comparisons of the
AUC between the groups, the method of DeLong
et al20 was used. Due to uncertainty regarding the opti-
mal cutoff for a “short cervix,” we investigated cutoffs of
10, 15, 20, and 25 mm and calculated the sensitivity,
specificity, positive predictive value, and negative predic-
tive value with 95% CIs for sPTB before 37 and
34 weeks at these cutoffs. We determined the number
needed to screen to detect a short cervix at each cutoff,
stratified by parity. Next, we compared the incidence of
a short cervix in patients who had sPTB by parity.
Finally, we conducted a sensitivity analysis excluding all
patients with an untreated short cervix or treatment
with any modality other than vaginal progesterone
alone.
Stata version 13 software (StataCorp, College Sta-
tion, TX) and SAS version 9.4 software (SAS Institute
Inc, Cary, NC) were used for the analysis. We did not
perform an a priori sample size calculation because there
is no well-established sample size calculation for compar-
ing the area under two ROC curves in independent sam-
ples. Two-sided P < .05 was considered significant.
Results
During the study period, a total of 20,100 patients
were eligible for screening. Of these, 2087 (10%)
declined. Patients who declined screening were more
likely to be multiparous (63% versus 57%; P < .001),
to be African American (42% versus 31%; P < .001),
to smoke tobacco (10% versus 6%; P < .001), and to
be older (mean age, 28.0 versus 29.4 years; P < .001)
and had a higher BMI (27.1 versus 26.5 kg/m2;
P = .002) compared to patients who accepted screen-
ing. Of the remaining 18,013 patients, 1648 (9%) had
a history of PTB, and 2857 (17% of the otherwise eli-
gible patients) had no outcome data available. Of the
remaining 13,508 patients, 5861 (43%) were nullipa-
rous, and 7647 (57%) were multiparous with no his-
tory of sPTB (Figure 1). Multiparous patients were
older and had a higher BMI than nulliparous patients.
Additionally, tobacco smoking was more common in the
multiparous group. Multiparous patients were screened
an average of 1 day later than nulliparous patients
(Table 1). Birth outcome data were missing from 17%
(2857) of otherwise eligible patients (1178 [41%] nullip-
arous patients and 1679 [59%] multiparous patients).
Patients with missing data were compared to the 13,508
patients for whom outcome data was available. The
mean CL was the same in nulliparous patients regardless
of the availability of outcome data and was 1 mm longer
in multiparous patients with outcome data available
(P < .001). Additionally, patients with missing outcome
data were more likely to smoke tobacco, but there were
no other significant differences between the group with
missing outcome data and the remainder of the patients.
Figure 1. Study flow diagram.
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Treatment data were available for 100 of the
122 patients (82%) with a CL of 20 mm or less. Of
these patients, 11 (11%) had no treatment; 61 (61%)
had vaginal progesterone alone; 2 (2%) had cerclage
alone; 1 (1%) had oral progesterone only; 3 (3%)
had 17-hydroxyprogesterone only; and 22 (22%) had
multiple therapies, including 17 (17%) with cerclage
and progesterone, 2 (2%) with multiple forms of pro-
gesterone, and 3 (3%) with a pessary, cerclage, and
progesterone.
The CL characteristics of each group as well as the
outcomes of sPTB before 37, 34, and 28 weeks are
shown in Table 2. Multiparous patients had a lower rate
of sPTB and a slightly longer mean CL (41.8 versus
39.9 mm; P < .001). Additionally, the 1st, 5th, and 10th
percentiles of CL were all shorter in nulliparous com-
pared to multiparous patients.
The ROC curves (Figures 2 and 3) showed that
TVCL screening performed marginally better in nullipa-
rous patients than in multiparous patients for prediction
of sPTB before 37 weeks, with AUCs of 0.67 (95% CI,
0.63–0.70) for nulliparous patients and 0.61 (95% CI,
0.57–0.63) for multiparous patients (P = .008). For
sPTB before 34 weeks, the AUCs were 0.74 (95% CI,
0.69–0.79) for nulliparous patients and 0.70 (95% CI,
0.64–0.76) for multiparous patients (P = .30).
The numbers of patients with and without PTB
for each group by CL cutoff are shown in Table 3.
The sensitivity was lower in multiparas, and the speci-
ficity was comparable between the groups (Table 4).
The same pattern was found for sPTB before 34 weeks
(Table 5).
Multiparous patients with sPTB were less likely to
have a short cervix compared to nulliparous patients
with sPTB. For instance, 58 of 379 (15.3%) of nullipa-
rous patients with sPTB had a CL of 25 mm or less,
whereas only 29 of 375 (7.7%) of multiparous patients





(n = 7647) Pa
Age, y 27.8  5.8 30.6  5.3 <.01
BMI, kg/m2 25.9  6.9 27.0  7.6 <.01
Obese
(BMI ≥30 kg/m2)
1137 (19.4) 1835 (24.0) <.001
Gestational age at
screening, wk
19.9  1.2 20.0  1.3 <.01
Tobacco use 260 (4.4) 586 (7.7) <.01
Race <.001
African American 1784 (30.4) 2422 (31.7)
White 3160 (53.9) 3885 (50.8)
Other or not
reported
917 (15.7) 1340 (17.5)
Data are presented as mean  SD and number (percent) where
applicable.
aFrom t test or χ2 test.





(n = 7647) Pa
Birth outcomes
sPTB <37 wk 379 (6.5) 375 (4.9) <.001
sPTB <34 wk 137 (2.3) 108 (1.4) <.001
sPTB <28 wk 53 (0.9) 47 (0.6) .052
CL outcomes
CL, mm 39.9  7.3 41.8  7.4 <.01
10th percentile, mm 32.0 33.0
5th percentile, mm 30.0 31.0
1st percentile, mm 19.0 24.0
CL ≤10 mm
(n = 34 [0.3%])
17 (0.29) 17 (0.22) .44
CL ≤15 mm
(n = 68 [0.5%])
40 (0.68) 28 (0.37) .010
CL ≤20 mm
(n = 122 [0.9%])
73 (1.25) 49 (0.64) <.001
CL ≤25 mm
(n = 207 [1.5%])
120 (2.05) 87 (1.14) <.001
CL in patients with
sPTB <37 wk
34.5  10.4 38.5  10.2 <.001
Data are presented as number (percent) and mean  SD where
applicable.
aFrom t test or χ2 test.
Figure 2. Receiver operating characteristic curves for CL and sPTB
before 37 weeks.
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with sPTB did (P = .001). The same was true at the
other CL cutoffs, except that at a cutoff of 10 mm, the
difference was no longer statistically significant.
The mean CL in multiparous patients with sPTB
before 37 weeks was greater than that in nulliparous
patients (34.5 versus 38.5 mm; P < .001). The num-
ber of patients needed to screen to detect a single
case of a short cervix was higher in multiparas com-
pared to nulliparas (Table 6).
In the sensitivity analysis excluding patients with an
untreated short cervix or treatment with modalities other
than vaginal progesterone alone (remaining 13,470),
there was no meaningful change in the results. The AUC
for the multiparous patients for sPTB before 37 weeks
was 0.60 (95% CI, 0.57–0.63), and for the nulliparous
patients, it was 0.65 (95% CI, 0.62–0.68; P = .026). Simi-
larly, the sensitivity, specificity, and negative and positive
predictive values at the different cutoffs were largely
unchanged in this group.
Discussion
We found that the midtrimester CL is on average longer
in multiparous patients without a history of sPTB com-
pared to nulliparous patients and that a short cervix is
less predictive of sPTB before 37 weeks in multiparous
compared to nulliparous patients. At any cutoff for a
short cervix, the number needed to screen to detect a
short cervix was lower in nulliparous patients, and there
was improved sensitivity for predicting sPTB. However,
there was no difference in the predictive ability of
midtrimester TVCL screening to predict sPTB before
34 weeks by parity. These findings call into question the
value of universal CL screening in multiparous patients
without a history of sPTB.
The differences in the predictive value can be
explained by the underlying prevalence of the disease
(sPTB), which varies in nulliparous versus multiparous
patients. However, there were also differences in the sen-
sitivity and specificity, which are inherent properties of
the test and are not related to the underlying prevalence
of disease. These differences in the sensitivity and speci-
ficity of CL screening by parity suggest that the mecha-
nism of sPTB may be different in multiparous compared
to nulliparous patients. This finding was supported by
the lower incidence of a short cervix in multiparous
patients with sPTB. Therefore, TVCL screening in mul-
tiparous patients may not assess for the underlying
mechanism of PTB in these patients.
To date, there have been only a few studies directly
comparing CL in nulliparous patients versus multiparous
ones with no history of sPTB. In a prospective study of
1569 patients with no history of preterm delivery under-
going TVCL screening, Orzechowski et al14 found that a
CL of 20 mm or less was more common in nulliparous
Figure 3. Receiver operating characteristic curves for CL and sPTB
before 34 weeks.
Table 3. Two × Two Tables of CL and Outcome by Parity


















≤10 15 2 13 4 9 8 9 8
>10 364 5480 124 5720 366 7264 99 7531
≤15 25 15 20 20 13 15 11 17
>15 354 5467 117 5704 362 7257 97 7522
≤20 42 31 31 42 20 29 16 33
>20 337 5451 106 5682 355 7243 92 7506
≤25 58 62 40 80 29 58 19 68
>25 321 5420 97 5644 346 7214 89 7471
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compared to multiparous patients, and there was no dif-
ference in the odds of sPTB in women with a short cervix
(≤20 mm) in multiparous versus nulliparous patients.
They also reported sensitivity and specificity of a cutoff of
20 mm or less for sPTB before 37 weeks that were some-
what higher than in our study (sensitivity, 20.0% versus
11.1%). Our study differs from their report in a few
important ways: our sample size was nearly 9 times larger;
we reported on the sensitivity and specificity of TVCL at
a number of possible cutoffs; and we used ROC curves to
better understand test characteristics. The differences in
sensitivity may have been due to different patient charac-
teristics; in their study, 44% of nulliparous patients were
African American, whereas in this study, only 30%were.14
Since CL is more predictive of sPTB in African American
compared to non–African American women, this differ-
ence in the demographic distribution may underlie the
differences in our findings.21
Similarly, Facco and Simhan15 noted that multip-
arous patients with no history of sPTB had a very low
incidence of a short cervix, and therefore, the number
needed to screen to prevent a single PTB was consid-
erably higher. On the contrary, in a recent large study
by Son et al,22 implementation of a universal CL screen-
ing program reduced the rate of sPTB, and this reduc-
tion did not differ based on parity. However, their study
differed from ours in that only 9.6% of the screened
patients were African American. In another example of
the way in which the underlying patient population may
affect the efficacy of TVCL screening and sPTB, a study
comparing outcomes from the Netherlands and Chicago
found similar CLs but an increased rate of sPTB before
32 weeks in the Netherlands.23 Another study from the
Netherlands found no difference in the ability of a short
cervix to predict sPTB in nulliparous compared to mul-
tiparous patients, although the underlying population
was quite different from our population.24
Our study had a number of strengths. First, there
were more than 13,000 patients in the study, representing
one of the largest studies on this topic to date. Second, all
patients underwent TVCL measurement using a stan-
dardized protocol in accordance with national guidelines.
Third, we had a robust database containing detailed clini-
cal and demographic information.
On the other hand, there were some limitations to
consider. Our study was retrospective; however, we had
accurate information regarding both the exposure (CL)
and the outcome from a validated database.17 Second,
there was heterogeneity in the treatments used for a
short cervix, although this has also been seen in similar
centers.22 In particular, only 61% of the patents in the
study had the recommended treatment (vaginal proges-
terone) for a short cervix, whereas an additional 17%
had progesterone in addition to a cerclage. The fact that
patients received different treatments and that not all
patients received the current recommended treatment
undoubtedly influenced our findings. At the same time,
the fact that not all patients accepted or received the rec-
ommended treatment may be more representative of the
general population, in which there is a diversity of practice
patterns.22 Although the fact that patients were treated
with any modality will affect the sensitivity and specificity
results (compared to an assessment of sensitivity and
specificity in untreated patients), this limitation is inher-
ent in any modern assessment of CL performance.14
Additionally, we had limited clinical information regard-
ing other risk factors for PTB, such as sexually transmitted
infections and prior dilation and curettage. Finally, there
was no delivery outcome available for 17% of patients. It
is possible that inclusion of these patients would have
changed the findings of the study, although these patients
did not have meaningful differences in clinical characteris-
tics or average CL measurements from those who had
delivery information.
In conclusion, the incidence of a short cervix is
lower in multiparous patients with no history of sPTB
compared to nulliparous patients. As a screening test,
TVCL performs worse in multiparous patients with no
history of sPTB. Consideration should be given to
whether a different cutoff should be used. Importantly,
the mean CL in patients with sPTB is well above
25 mm and is even higher in multiparous patients, limit-
ing the sensitivity of TVCL screening, findings that have
been seen elsewhere.24 The clinical utility of TVCL
screening for prediction of sPTB might be optimized by
applying the test in a more nuanced fashion: eg, in
patients at higher risk for PTB and with graded cutoffs
Table 6. Numbers Needed to Screen to Detect a Short Cervix by
Parity
CL, mm Nulliparous (n = 5861) Multiparous (n = 7647)
≤10 345 (215–554) 450 (280–723)
≤15 146 (108–200) 273 (189–395)
≤20 80 (64–101) 156 (118–206)
≤25 49 (41–58) 88 (71–108)
Data are presented as number (95% CI).
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for the diagnosis of a short cervix based on clinical char-
acteristics. Finally, the results from this study could be
used for a cost-effectiveness analysis of universal CL
screening in nulliparous versus multiparous patients.
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